(Q48201230)

9 February 2018

title

Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial (English)

1 reference

9 February 2018

author name string

Andrew J Cutler

1

1 reference

9 February 2018

Amir H Kalali

2

1 reference

9 February 2018

Greg W Mattingly

3

1 reference

9 February 2018

Jelena Kunovac

4

1 reference

9 February 2018

Xiangyi Meng

5

1 reference

9 February 2018

publication date

14 January 2013

1 reference

9 February 2018

published in

C N S Spectrums

1 reference

9 February 2018

volume

18

1 reference

9 February 2018

issue

1

1 reference

9 February 2018

page(s)

43-54

1 reference

9 February 2018

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000764

Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000764

Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000764

Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000764

A rating scale for drug-induced akathisia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000764

Manual for the Extrapyramidal Symptom Rating Scale (ESRS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000764

Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000764

Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000764

Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000764

Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000764

Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000764

Size of burden of schizophrenia and psychotic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000764

Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000764

Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000764

A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000764

Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000764

A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000764

EPS profiles: the atypical antipsychotics are not all the same

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000764

Absence of weight gain association with the HTR2C -759C/T polymorphism in patients with schizophrenia treated with iloperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000764

Clinical potential of lurasidone in the management of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000764

7 January 2021

Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000764

7 January 2021

A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000764

7 January 2021

A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000764

7 January 2021

10.1017/S1092852912000764

Identifiers

DOI

1 reference

9 February 2018

1 reference

9 February 2018